Key takeaways
- Revolution Medicines isn't profitable, but it has a drug with blockbuster potential.
- Shares of Revolution Medicines (RVMD) have taken off so far this year, rising more than 150%.
- Revolution lost $407.5 million, compared to a loss of 305.2 million in the same quarter a year ago.
Its lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer. The young drug company has a revolutionary pipeline of RAS-inhibitor therapies.
See the latest quote, chart and news for RVMD.
